Clinical trials: Liver Inflammation
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Chronic Hepatitis B Infection
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209011
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yao Xie
HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Trial name
- ELIMINATE-B (NCT06680232)
- Testing
- PBGENE-HBV
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Hepatitis C Virus Infection, Response to Therapy of
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to : 1.
- Trial name
- NCT01572233
- Testing
- Personalized Physical Activity and Psycho-Education (PPAPE) Program
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
HIV Infections, Hepatitis C
Effects of HIV and Hepatitis C Virus on the Brain
This study will determine the effects that HIV and hepatitis C virus have on thinking abilities and whether the viruses affect brain chemistry.
- Trial name
- NCT00494936
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic Hepatitis B
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
Patients with a confirmed diagnosis of chronic hepatitis B (CHB) who have complete clinical data and retained blood or liver tissue samples will be enrolled.
- Trial name
- HBV IMDR (NCT06779864)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis B
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic…
- Trial name
- NCT04971928
- Testing
- GSK3228836
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate.
- Trial name
- NCT01599130
- Testing
- Entecavir, Peginterferon alfa-2a
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis b
TAF Real World Study for Universal Effectiveness
This study is a multi-center, prospective, real-world study, males and non-pregnant, non-lactating female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or…
- Trial name
- TRUE (NCT03752658)
- Testing
- Tenofovir Alafenamide
- Where
- 7 sites in China
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Chronic Hepatitis C Virus
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
The study aims to study the outcome of pharmacokinetics-adjusted dose ribavirin (plus pegIFN) on the SVR in chronic HCV patients.
- Trial name
- NCT01686789
- Testing
- Pegylated interferon alpha-2a
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 181 people
- Sponsor
- King Abdulaziz Medical City
Non-Alcoholic Fatty Liver Disease, Liver Fat
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fat, Obesity, Inflammation
- Trial name
- NCT05968378
- Testing
- Standard healthy eating advice, eTRE plus Mediterranean diet
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University College Dublin
Hepatitis C, Substance Use Disorders
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
hepatitis C virus (HCV) has traditionally been treated in subspecialty health centers given the complexity of older pegylated interferon containing regimens, formerly the standard of care.
- Conditions
- Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
- Trial name
- NCT03093415
- Testing
- elbasvir-grazoprevir (50 mg/100 mg)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oregon Health and Science University
Hepatitis C, Chronic
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
The purpose of this study is to evaluate the efficacy (proportion of subjects with SVR12), safety, tolerability and pharmacokinetics of an 8- and 6-week treatment regimen of AL-335, odalasvir (ODV) and simeprevir (SMV) in chronic…
- Trial name
- NCT02765490
- Testing
- AL-335, Odalasvir, Simeprevir
- Where
- 28 sites in Belgium, Canada and 4 more
- Volunteers
- 365 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis
VaxTeen Hepatitis B Vaccine Booster Study
The purpose of this study is to determine immune status of adolescents who responded to a primary series of recombinant hepatitis B vaccine given at birth and to assess their response to a booster dose of vaccine.
- Trial name
- NCT00144313
- Testing
- hepatitis B vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis A, Hepatitis A Virus
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- HAV-2 (NCT06978621)
- Testing
- Inactivated hepatitis A vaccine (I-HAV)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Hepatitis C, HIV
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine.
- Trial name
- NCT01427504
- Testing
- boceprevir; etravirine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cholangitis, Sclerosing, Hepatitis, Autoimmune
Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH
MERLIN is an adaptive, single arm, multi-centre, phase IIa multi-disease clinical trial. It is designed to: i) Determine dose safety of ORBCEL-C™ (selected Mesenchymal stromal cells derived from human umbilical cord) ii) Evaluate…
- Trial name
- Merlin (NCT02997878)
- Testing
- Orbcel-C
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Birmingham
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.